<DOC>
	<DOCNO>NCT00005617</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may make body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy treat patient stage IV , relapse malignant melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IV Relapsed Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety administer MART-1 peptide-pulsed dendritic cell patient stage IV relapse malignant melanoma . - Determine immunological clinical response patient population therapy . OUTLINE : This dose-escalation study . Patients undergo leukapheresis day -14 -8 . Mononuclear cell isolate , use generate dendritic cell ( DC ) , pulse MART-1 peptide . Patients vaccinate MART-1 peptide-pulsed DC either IV intradermally day 0 , 14 , 28 . Cohorts 3-6 patient receive escalate dos MART-1 peptide-pulsed DC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow death . PROJECTED ACCRUAL : A total 18-24 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adults age 18 malignant melanoma . HLAA2.1 positive express MART1 , assess either RTPCR immunohistochemistry Tumor stag T3N0M0 great eligible trial accord follow : 1 . I ( &lt; .75 1.5 mm Clark level IIIT12N0M0 ) —not eligible 2 . II ( 1.5 4 mm level IVT3N0M0 ) —eligible 3 . III ( limited nodal metastasis involve one regional lymph node basin , few 5 intransit metastasis TxN1M0 ) —eligible 4 . IV ( advanced regional metastasis TxN2M0 distant metastasis TxNxM1 ) —eligible 5 . Relapsed melanoma—eligible Patients previously treat form therapy either metastatic , relapsed primary melanoma eligible trial , provide previous treatment complete &gt; 30 day prior enrollment Both male female may enrol . Premenopausal females must negative pregnancy test prior treatment Karnofsky Performance Status great equal 70 percent No previous evidence class 3 great New York Heart Association cardiac insufficiency coronary artery disease No previous evidence opportunistic infection A minimum 30 day must elapse since completion prior chemotherapy , immunotherapy radiation therapy Adequate baseline hematological function assess follow laboratory value within 30 day prior study entry ( day 30 0 ) : 1 . Hemoglobin &gt; 9.0 g/dl 2 . Platelets &gt; 100000/mm3 3 . WBC &gt; 3000/mm3 4 . Absolute Neutrophil Count &gt; 1000/mm3 Positive skin test common antigen ( tetanus candida ) Ability give inform consent Lactating female female childbearing potential must negative serum betaHCG pregnancy test Acute infection : acute viral , bacterial , fungal infection require specific therapy . Acute therapy must complete within 14 day prior study treatment HIVinfected patient Acute medical problem ischemic heart lung disease may consider unacceptable anesthetic operative risk Patients underlying condition would contraindicate therapy study treatment ( allergies reagent use study ) Patients organ allograft Uncontrolled CNS metastasis . Patients CNS metastasis eligible receive CNS irradiation control local tumor growth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>